LeMaitre Vascular

LeMaitre Vascular

LeMaitre Vascular is a publicly traded medical device company headquartered in Burlington, Massachusetts. George LeMaitre, a former physician assistant, founded the company in 1986. The firm is not a family office or institutional allocator. It is an operating business that designs, manufactures, and sells vascular surgical devices and implants to hospitals globally. The company's product portfolio focuses on niche vascular surgery segments, including shunts, grafts, and balloon catheters used in open vascular surgeries. Its growth strategy has historically relied on acquiring underperforming vascular product lines from larger device manufacturers, then integrating them into its global direct-sales force. Key product families include the XenoSure biologic patch, the Pruitt F3 carotid shunt, and the Albograft polyester graft. The firm sells into regions covering North America, Europe, and Asia-Pacific. LeMaitre Vascular operates through direct sales offices in the United States, Canada, Germany, the United Kingdom, Italy, Spain, France, Switzerland, Japan, China and other markets. As a public company on Nasdaq, its scale is measured by revenue and market capitalization, not assets under management. It does not invest third-party capital, nor does it have a fund structure, co-investment vehicles, or philanthropic foundations related to family wealth. In February 2024, the company reported fourth-quarter 2023 revenue of $48.9 million, up 19% organically year-over-year, per the firm's quarterly earnings release. The structural differentiator lies in its focused manufacturing and distribution engine for niche, open-surgery devices. Unlike a diversified medical conglomerate, LeMaitre concentrates exclusively on a narrow band of vascular products where it can achieve significant market share through in-house production and a dedicated sales team, insulating it somewhat from trends in less invasive endovascular procedures.